CTMC

Rice Biotech Launch Pad adds William McKeon to external advisory board

Retrieved on: 
Thursday, March 14, 2024
Harris Health System, Research, Launch pad, Growth, Bill, Goldman Sachs, Rice University, Trustee, Integration, Patient, Stanford University Medical Center, Neuroscience, University, Faculty, Medtronic, MicroPort, CTMC, Roger Williams University, Texas Medical Center, Argonne National Laboratory, Rice, Jefferies, Greater Houston Partnership, College of Engineering (KNUST), MD Anderson Cancer Center, McKeon, Pharmaceutical industry

HOUSTON, March 14, 2024 /PRNewswire/ -- Rice University today announced the addition of William McKeon to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.

Key Points: 
  • HOUSTON, March 14, 2024 /PRNewswire/ -- Rice University today announced the addition of William McKeon to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "The appointment of a figure like Bill McKeon, who heads the largest medical city in the world at TMC, to the Launch Pad's external advisory board marks another highpoint of our commitment to the city of Houston," said Paul Wotton , executive director and chairman of the Rice Biotech Launch Pad.
  • "We are delighted to welcome Bill McKeon to the Launch Pad's remarkable external advisory board as he is a truly skilled leader whose local influence and strategic guidance will help elevate the Rice Biotech Launch Pad as a source for clinical advancements," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the accelerator.
  • "I am honored to join the exceptional advisory board of the Rice Biotech Launch Pad," said McKeon.

Rice Biotech Launch Pad adds pharmaceuticals pioneer Robert Ruffolo to external advisory board

Retrieved on: 
Monday, January 8, 2024
Eli Lilly and Company, MD Anderson Cancer Center, Pfizer, Faculty, Book, Launch pad, Argonne National Laboratory, Goldman Sachs, Integration, Drug development, CTMC, Research, Neuroscience, Harris Health System, Jefferies, Rice University, Ohio State University, Texas Medical Center, Doctor of Philosophy, Pharmacology, Bill, Patient, College of Engineering (KNUST), Rice, Pharmaceutical industry

HOUSTON, Jan. 8, 2024 /PRNewswire/ -- Rice University today announced the addition of Robert Ruffolo Jr. to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.

Key Points: 
  • HOUSTON, Jan. 8, 2024 /PRNewswire/ -- Rice University today announced the addition of Robert Ruffolo Jr. to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "Dr. Ruffolo brings immense value to the Rice Biotech Launch Pad as an adviser to drive drug development," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the Launch Pad.
  • "The Rice Biotech Launch Pad is one of the most forward-looking and technologically innovative teams in the drug development space right now," Ruffolo said.
  • Ruffolo is the 13th member of the Launch Pad's external advisory board.

KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

Retrieved on: 
Wednesday, November 29, 2023
Lung cancer, TIL, Food, Partnership, SOCS1, IND, CTMC, FDA, Cell, CRISPR, Trial of the century, Melanoma, MD Anderson Cancer Center, Therapy, Cancer, Monroe Dunaway Anderson, KSQ, Investigational New Drug, Head, HNSCC, Patient, Safety, University, TILS, NSCLC, Pharmaceutical industry

KSQ-001EX consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing.

Key Points: 
  • KSQ-001EX consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing.
  • Through our platform insights, we've identified how to enhance the effectiveness of T cells in the treatment of solid tumors.
  • We believe our eTIL® cell therapies have tremendous potential to benefit patients with cancer who have limited treatment options.
  • “Our partnership with CTMC has yielded a robust manufacturing process for our eTIL® cell therapy that is derived from patient tumor samples, including core biopsies.

Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Therapy, ICI, RECIST, University, National Resilience Institute, Disease, Patient, IL15, Monroe Dunaway Anderson, Neoplasm, DCR, ORR, Melanoma, IL2, CTMC, MD Anderson Cancer Center, TIL, Pharmaceutical industry, Obsidian

OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.

Key Points: 
  • OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.
  • , professor of Melanoma Medical Oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center.
  • “The OBX-115 data show its potential to be a meaningful advancement in the treatment of metastatic melanoma and TIL cell therapy,” said Parameswaran Hari, M.D., M.S., Chief Development Officer of Obsidian Therapeutics.
  • “These positive results underscore the potential for OBX-115 TIL cell therapy to offer patients with metastatic melanoma a differentiated TIL therapy without the need for IL2,” said Madan Jagasia, M.D., M.S., CEO of Obsidian Therapeutics.

Rice Biotech Launch Pad expands external advisory board with Kevin Sheridan

Retrieved on: 
Tuesday, October 17, 2023
Neuroscience, Jefferies, MBA, Bill & Melinda Gates Foundation, Massachusetts Institute of Technology, CTMC, Faculty, Rice, Launch pad, Columbia Business School, Rutgers University, Goldman Sachs, Rice University, Biotechnology, Green Launching Pad, MD Anderson Cancer Center, Harris Health System, Argonne National Laboratory, College of Engineering (KNUST), Growth, Chemistry, Geisinger Commonwealth School of Medicine, ApiJect Systems, Research, Integration, UBS, Pharmaceutical industry, Management

HOUSTON, Oct. 17, 2023 /PRNewswire/ -- Rice University today announced the addition of Kevin Sheridan to its external advisory board for the Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures. 

Key Points: 
  • HOUSTON, Oct. 17, 2023 /PRNewswire/ -- Rice University today announced the addition of Kevin Sheridan to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "With the formation of the external advisory board earlier this month , the Rice Biotech Launch Pad is well-positioned to stand out among other accelerators and to have a meaningful impact on the biotech industry with the invaluable insights provided by the board," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the accelerator.
  • "Kevin is the next piece of the puzzle to building out the phenomenal group of executives that comprise our external advisory board.
  • Sheridan is the 12th member of the Launch Pad's external advisory board.

KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapies for the Treatment of Solid Tumors

Retrieved on: 
Wednesday, September 6, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, SOCS1, CTMC, Partnership, TIL, KSQ, Etiler, National Resilience Institute, Patient, Engineering, PD-1, Therapy, IND, MD Anderson Cancer Center, Tumor microenvironment, Pharmaceutical industry, Vaccine

"Our eTIL programs – which edit the SOCS1 and Regnase-1 genes – have the potential to be first- and best-in-class cell therapies for cancer treatment.

Key Points: 
  • "Our eTIL programs – which edit the SOCS1 and Regnase-1 genes – have the potential to be first- and best-in-class cell therapies for cancer treatment.
  • As our eTIL programs move through IND-enabling studies, our partnership with CTMC will have us ready to manufacture KSQ-001EX and KSQ-004EX for clinical studies," said Qasim Rizvi, Chief Executive Officer of KSQ.
  • "We believe our eTIL programs have the potential to address the significant unmet need in the solid tumor space."
  • "TIL therapies have tremendous potential for the treatment of solid tumors as they are naturally selected to target a host of tumor antigens specific to the patient.

CTMC Marks One Year of Accelerating Life-Saving Cell Therapies to Patients

Retrieved on: 
Monday, June 5, 2023
Research, General Health, Oncology, Other Manufacturing, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Health, Other Science, Manufacturing, Obsidian, BIO, Therapy, TIL, Food and Drug Administration, Cancer, Monroe Dunaway Anderson, CAR, Environmental monitoring, Texas Medical Center, Investigational New Drug, CGMP, Patient, IND, MD Anderson Cancer Center, Food, Calibration, Pharmaceutical industry, CTMC

CTMC , a joint venture between MD Anderson Cancer Center and Resilience, celebrates one year since its founding to accelerate life-saving cell therapies reaching patients.

Key Points: 
  • CTMC , a joint venture between MD Anderson Cancer Center and Resilience, celebrates one year since its founding to accelerate life-saving cell therapies reaching patients.
  • In September 2022, CTMC partnered with Ori Biotech to accelerate development of new cell therapies using Ori’s cell therapy manufacturing platform.
  • In March 2023, CTMC unveiled four new cleanrooms totaling 2,700 square feet to expand its manufacturing space dedicated solely to cell therapies.
  • Just steps away from MD Anderson Cancer Center, CTMC drives life-saving cell therapies from the pre-clinical stage through regulatory filing into clinical development.

CTMC Awarded $9.1M Through CPRIT Grant for the Advancement of Cell Therapy

Retrieved on: 
Thursday, May 18, 2023
Science, Other Science, Biotechnology, Research, Oncology, Health, Clinical Trials, Other Health, TIL, Cancer, Monroe Dunaway Anderson, RVV, Patient, Risk, Resilience, Ecosystem, Emerging technologies, Pharmaceutical industry, CTMC

CTMC , a joint venture between Resilience + MD Anderson Cancer Center, announces that it has been awarded $9.1M in the newly created Cancer Prevention & Research Institute of Texas (CPRIT) Texas New Technologies Company grant.

Key Points: 
  • CTMC , a joint venture between Resilience + MD Anderson Cancer Center, announces that it has been awarded $9.1M in the newly created Cancer Prevention & Research Institute of Texas (CPRIT) Texas New Technologies Company grant.
  • The grant will focus on retroviral vector (RVV) manufacturing, an enhanced tumor-infiltrating lymphocytes (TIL) platform, and a differentiated process development approach to CAR-T manufacturing.
  • CPRIT created a new grant category called Texas New Technologies Company to fund development projects of promising technologies.
  • CTMC works in collaboration with both academic faculty at MD Anderson and with biopharmaceutical companies to drive life-saving cell therapies from the pre-clinical stage through regulatory filing to clinical trials.

Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy

Retrieved on: 
Tuesday, December 20, 2022
Cancer, Investigational New Drug, Pharmacokinetics, PI, Food, Therapy, MD, Monroe Dunaway Anderson, Haematopoietic system, CAR, Patient, Safety, FDA, CTMC, IND, Food and Drug Administration, Diagnosis, Pharmaceutical industry

HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.

Key Points: 
  • , professor of Investigational Cancer Therapeutics at MD Anderson and co-PI Samer Srour, M.D., assistant professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson.
  • All participants will be asked to enter the long-term follow up (LTFU) study as per FDA standard requirement for all gene and cell therapies.
  • “CTMC was created to accelerate impactful cell therapies reaching patients," said Jason Bock, CEO of CTMC.
  • “We believe IVS-3001 therapy has the potential to significantly transform the treatment landscape for cancer patients and the potential to achieve improved clinical outcomes.”

Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy

Retrieved on: 
Monday, December 19, 2022
Cancer, Investigational New Drug, Pharmacokinetics, PI, Food, Therapy, MD, Monroe Dunaway Anderson, Haematopoietic system, CAR, Patient, Safety, FDA, CTMC, IND, Food and Drug Administration, Diagnosis, Pharmaceutical industry

HOUSTON, Texas, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.

Key Points: 
  • , professor of Investigational Cancer Therapeutics at MD Anderson and co-PI Samer Srour, M.D., assistant professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson.
  • All participants will be asked to enter the long-term follow up (LTFU) study as per FDA standard requirement for all gene and cell therapies.
  • “CTMC was created to accelerate impactful cell therapies reaching patients," said Jason Bock, CEO of CTMC.
  • “We believe IVS-3001 therapy has the potential to significantly transform the treatment landscape for cancer patients and the potential to achieve improved clinical outcomes.”